Australia's Cleo Diagnostics jumps on US clinical trials for cancer blood test

CLEO Diagnostics

06/09/2024 02:13

** Shares of Cleo Diagnostics  COV.AX  rise as much as 4.2%
to A$0.375, set for best days since Aug. 26, if gains hold     
    ** Cancer diagnostics co announces commencement of U.S.
clinical trials for its ovarian cancer diagnostic blood test
    ** Trial will validate the use of the ovarian cancer blood
test for the U.S. market - co
    ** COV up 105.7% YTD as of last close

 (Reporting by Adwitiya Srivastava in Bengaluru)
 ((Adwitiya.Srivastava@thomsonreuters.com;))